Tech Company Financing Transactions
Intarcia Therapeutics Funding Round
Alta Partners, GGV Capital and New Enterprise Associates invested in a $50 million Series E funding round for Intarcia Therapeutics. The round was announced on 12/1/2004.
Transaction Overview
Company Name
Announced On
12/1/2004
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series E
Investors
Proceeds Purpose
The $50 million raised in this round will allow us to achieve a number of key clinical milestones and will provide additional strategic flexibility.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 13 Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kurt Graves
Chief Scientific Officer
Andrew Young
VP - Client Services
Jay Smith
VP - General Counsel
Raymond Keane
VP - Human Resources
James Brady
VP - Manufacturing
Thomas Alessi
Browse more venture capital transactions:
Prev: 12/1/2004: Bsafe Information Systems venture capital transaction
Next: 12/2/2004: Radianse venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs